MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598133 | Name: A2-Binding peptide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A2-Binding peptide has a substitution of lysine at position 62 of MP 57-68, K62, KGILGKVFTLTV; from influenza A matrix protein, involved in assembly of MHC Class I molecules.

Chemical Structure

A2-Binding peptide
A2-Binding peptide
CAS#119425-35-3

Theoretical Analysis

MedKoo Cat#: 598133

Name: A2-Binding peptide

CAS#: 119425-35-3

Chemical Formula: C61H106N14O15

Exact Mass: 1274.7962

Molecular Weight: 1275.60

Elemental Analysis: C, 57.44; H, 8.38; N, 15.37; O, 18.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
A2-Binding peptide;
IUPAC/Chemical Name
L-lysylglycyl-L-isoleucyl-L-leucylglycyl-L-lysyl-L-valyl-L-phenylalanyl-L-threonyl-D-leucyl-L-threonyl-L-valine
InChi Key
NBOKFONQQZRHRY-DINGYSCKSA-N
InChi Code
InChI=1S/C61H106N14O15/c1-13-36(10)49(71-46(79)31-65-52(80)40(64)23-17-19-25-62)58(86)68-42(27-32(2)3)53(81)66-30-45(78)67-41(24-18-20-26-63)54(82)72-47(34(6)7)57(85)70-44(29-39-21-15-14-16-22-39)56(84)74-50(37(11)76)59(87)69-43(28-33(4)5)55(83)75-51(38(12)77)60(88)73-48(35(8)9)61(89)90/h14-16,21-22,32-38,40-44,47-51,76-77H,13,17-20,23-31,62-64H2,1-12H3,(H,65,80)(H,66,81)(H,67,78)(H,68,86)(H,69,87)(H,70,85)(H,71,79)(H,72,82)(H,73,88)(H,74,84)(H,75,83)(H,89,90)/t36-,37+,38+,40-,41-,42-,43+,44-,47-,48-,49-,50-,51-/m0/s1
SMILES Code
CC(C)[C@@H](C(O)=O)NC([C@H]([C@H](O)C)NC([C@@H](CC(C)C)NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@H](CCCCN)NC(CNC([C@@H](NC([C@H]([C@@H](C)CC)NC(CNC([C@H](CCCCN)N)=O)=O)=O)CC(C)C)=O)=O)=O)C(C)C)=O)Cc1ccccc1)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,275.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang P, Vánky F, Végh Z, Persson U, Hising C, Klein E. Assembly of MHC class I molecules in ex vivo carcinoma cells induced by IFN-gamma or by a binding peptide. Cell Immunol. 1992 Jul;142(2):296-302. PubMed PMID: 1623553. 2: Kanaoka S, Yamasaki S, Okino T, Inoue N, Shimada Y, Kaneko M, Otaka A, Fujii N, Imamura M. Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient. J Surg Oncol. 1999 May;71(1):16-21. PubMed PMID: 10362086. 3: Tung CW, Ziehm M, Kämper A, Kohlbacher O, Ho SY. POPISK: T-cell reactivity prediction using support vector machines and string kernels. BMC Bioinformatics. 2011 Nov 15;12:446. doi: 10.1186/1471-2105-12-446. PubMed PMID: 22085524; PubMed Central PMCID: PMC3228774. 4: Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Röder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, Knop J, Bröcker EB, Enk A, Kämpgen E, Schuler G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000 Sep 15;165(6):3492-6. PubMed PMID: 10975870. 5: Barrett J, Guimaraes A, Cullis J, Goldman JM. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia. Stem Cells. 1993 Oct;11 Suppl 3:104-8. PubMed PMID: 8298471.